Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-miR-20a
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Intrathecal, Intravitreal, Inhalation, Intranasal, Intratumoral, Intradermal, Oral, Parenteral
01
Overview
anti-miR-20a refers to a class of antisense oligonucleotides or synthetic molecules designed to bind and inhibit the function of microRNA-20a (miR-20a). miR-20a is a member of the miR-17-92 cluster and is frequently overexpressed in various malignancies, including breast cancer, where it acts as an oncomir by downregulating tumor suppressors such as PTEN. By sequestering or promoting the degradation of miR-20a, anti-miR-20a agents aim to restore the expression of target genes, thereby inhibiting oncogenic signaling pathways like PI3K/Akt and suppressing cell proliferation, invasion, and drug resistance. While primarily used in preclinical research, targeting the miR-20a axis is considered a potential therapeutic strategy for cancer treatment.
- Other names
- miR-20a inhibitormiR20a inhibitormiR 20a inhibitorantisense miR-20a
02
Targets
miR-20 family seed-sharing miRNAsmiR-20a (microRNA-20a)
Beyond the preview
Go deeper on anti-miR-20a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-miR-20a.